Patent assignee · CH · COMPANY

DERMAVANT SCIENCES GMBH

20Patents
20Active
20Granted
54Portfolio score

Filing activity: Dec 9, 2015 → Oct 20, 2023

Most-cited patents

PatentTitleAreaCited byStatus
US10195160B2 Topical pharmaceutical compositions Emerging Cross-Sectional Technologies 13 Active
US10376475B2 Method of use Human Necessities 7 Active
US10426743B2 Topical pharmaceutical compositions Emerging Cross-Sectional Technologies 3 Active
US10647649B2 Process for preparing tapinarof Chemistry; Metallurgy 3 Active
US10961175B2 Process for preparing tapinarof Chemistry; Metallurgy 2 Active
US11617724B2 Topical pharmaceutical compositions Human Necessities 1 Active
US11590088B2 Use of Tapinarof for the treatment of chronic plaque psoriasis Human Necessities 1 Active
US10357495B2 Topical formulations of PDE-4 inhibitors and their methods of use Human Necessities 1 Active
US11827605B2 Isoquinoline compounds and their use in treating AhR imbalance Chemistry; Metallurgy 1 Active
US11622945B2 Topical pharmaceutical compositions Emerging Cross-Sectional Technologies 0 Active
US12252471B2 Isoquinoline compounds and their use in treating AhR imbalance Chemistry; Metallurgy 0 Active
US11548853B2 Isoquinoline compounds and their use in treating AhR imbalance Chemistry; Metallurgy 0 Active
US10206925B2 Topical formulations of PDE-4 inhibitors and their methods of use Human Necessities 0 Active
US11497718B2 Use of tapinarof for the treatment of atopic dermatitis Human Necessities 0 Active
US11612573B2 Topical pharmaceutical compositions Emerging Cross-Sectional Technologies 0 Active
US11458108B2 Topical pharmaceutical compositions Emerging Cross-Sectional Technologies 0 Active
US11597692B2 Process for preparing tapinarof Chemistry; Metallurgy 0 Active
US12275696B2 Process for preparing tapinarof Chemistry; Metallurgy 0 Active
US11267788B2 Isoquinoline compounds and their use in treating AhR imbalance Chemistry; Metallurgy 0 Active
US11938099B2 Use of tapinarof for the treatment of atopic dermatitis Human Necessities 0 Active

Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.